Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Chewable & Orodispersible Aids
Taste Masking
Direct Compression
Disintegrants & Superdisintegrants
Co-Processed Excipients
Parenteral
Granulation
Solubilizers
Thickeners and Stabilizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
65
PharmaCompass offers a list of Carboplatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Carboplatin manufacturer or Carboplatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carboplatin manufacturer or Carboplatin supplier.
PharmaCompass also assists you with knowing the Carboplatin API Price utilized in the formulation of products. Carboplatin API Price is not always fixed or binding as the Carboplatin Price is obtained through a variety of data sources. The Carboplatin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Bristol-Myers Squibb Brand of Carboplatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bristol-Myers Squibb Brand of Carboplatin, including repackagers and relabelers. The FDA regulates Bristol-Myers Squibb Brand of Carboplatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bristol-Myers Squibb Brand of Carboplatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bristol-Myers Squibb Brand of Carboplatin supplier is an individual or a company that provides Bristol-Myers Squibb Brand of Carboplatin active pharmaceutical ingredient (API) or Bristol-Myers Squibb Brand of Carboplatin finished formulations upon request. The Bristol-Myers Squibb Brand of Carboplatin suppliers may include Bristol-Myers Squibb Brand of Carboplatin API manufacturers, exporters, distributors and traders.
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bristol-Myers Squibb Brand of Carboplatin DMF (Drug Master File) is a document detailing the whole manufacturing process of Bristol-Myers Squibb Brand of Carboplatin active pharmaceutical ingredient (API) in detail. Different forms of Bristol-Myers Squibb Brand of Carboplatin DMFs exist exist since differing nations have different regulations, such as Bristol-Myers Squibb Brand of Carboplatin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bristol-Myers Squibb Brand of Carboplatin DMF submitted to regulatory agencies in the US is known as a USDMF. Bristol-Myers Squibb Brand of Carboplatin USDMF includes data on Bristol-Myers Squibb Brand of Carboplatin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bristol-Myers Squibb Brand of Carboplatin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Bristol-Myers Squibb Brand of Carboplatin Drug Master File in Japan (Bristol-Myers Squibb Brand of Carboplatin JDMF) empowers Bristol-Myers Squibb Brand of Carboplatin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Bristol-Myers Squibb Brand of Carboplatin JDMF during the approval evaluation for pharmaceutical products. At the time of Bristol-Myers Squibb Brand of Carboplatin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Bristol-Myers Squibb Brand of Carboplatin Drug Master File in Korea (Bristol-Myers Squibb Brand of Carboplatin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Bristol-Myers Squibb Brand of Carboplatin. The MFDS reviews the Bristol-Myers Squibb Brand of Carboplatin KDMF as part of the drug registration process and uses the information provided in the Bristol-Myers Squibb Brand of Carboplatin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Bristol-Myers Squibb Brand of Carboplatin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Bristol-Myers Squibb Brand of Carboplatin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin suppliers with KDMF on PharmaCompass.
A Bristol-Myers Squibb Brand of Carboplatin CEP of the European Pharmacopoeia monograph is often referred to as a Bristol-Myers Squibb Brand of Carboplatin Certificate of Suitability (COS). The purpose of a Bristol-Myers Squibb Brand of Carboplatin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Bristol-Myers Squibb Brand of Carboplatin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Bristol-Myers Squibb Brand of Carboplatin to their clients by showing that a Bristol-Myers Squibb Brand of Carboplatin CEP has been issued for it. The manufacturer submits a Bristol-Myers Squibb Brand of Carboplatin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Bristol-Myers Squibb Brand of Carboplatin CEP holder for the record. Additionally, the data presented in the Bristol-Myers Squibb Brand of Carboplatin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Bristol-Myers Squibb Brand of Carboplatin DMF.
A Bristol-Myers Squibb Brand of Carboplatin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Bristol-Myers Squibb Brand of Carboplatin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin suppliers with CEP (COS) on PharmaCompass.
A Bristol-Myers Squibb Brand of Carboplatin written confirmation (Bristol-Myers Squibb Brand of Carboplatin WC) is an official document issued by a regulatory agency to a Bristol-Myers Squibb Brand of Carboplatin manufacturer, verifying that the manufacturing facility of a Bristol-Myers Squibb Brand of Carboplatin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bristol-Myers Squibb Brand of Carboplatin APIs or Bristol-Myers Squibb Brand of Carboplatin finished pharmaceutical products to another nation, regulatory agencies frequently require a Bristol-Myers Squibb Brand of Carboplatin WC (written confirmation) as part of the regulatory process.
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bristol-Myers Squibb Brand of Carboplatin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bristol-Myers Squibb Brand of Carboplatin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bristol-Myers Squibb Brand of Carboplatin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bristol-Myers Squibb Brand of Carboplatin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bristol-Myers Squibb Brand of Carboplatin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bristol-Myers Squibb Brand of Carboplatin suppliers with NDC on PharmaCompass.
Bristol-Myers Squibb Brand of Carboplatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bristol-Myers Squibb Brand of Carboplatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bristol-Myers Squibb Brand of Carboplatin GMP manufacturer or Bristol-Myers Squibb Brand of Carboplatin GMP API supplier for your needs.
A Bristol-Myers Squibb Brand of Carboplatin CoA (Certificate of Analysis) is a formal document that attests to Bristol-Myers Squibb Brand of Carboplatin's compliance with Bristol-Myers Squibb Brand of Carboplatin specifications and serves as a tool for batch-level quality control.
Bristol-Myers Squibb Brand of Carboplatin CoA mostly includes findings from lab analyses of a specific batch. For each Bristol-Myers Squibb Brand of Carboplatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bristol-Myers Squibb Brand of Carboplatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Bristol-Myers Squibb Brand of Carboplatin EP), Bristol-Myers Squibb Brand of Carboplatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bristol-Myers Squibb Brand of Carboplatin USP).
